ProBio: an outcome-adaptive, multi-arm, open-label, multiple assignment randomized biomarker-driven trial in patients with metastatic castration-resistant prostate cancer Ghent University
Androgen deprivation therapy (ADT) is the Standard systemic therapy for men with advanced prostate cancer. Although initially beneficial, inevitably all patients will progress to the lethal castration-resistant state of the disease. Metastatic castration-resistant prostate cancer (mCRPC) affects approximately 1.500-2.000 men in Belgium every year. Cytotoxic chemotherapy and newer endocrine agents are available, but they are expensive and ...